Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash & Equivalents (2021 - 2025)

Lyra Therapeutics has reported Cash & Equivalents over the past 5 years, most recently at $15.9 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $15.9 million for Q4 2025, down 60.83% from a year ago — trailing twelve months through Dec 2025 was $15.9 million (down 60.83% YoY), and the annual figure for FY2025 was $15.9 million, down 60.83%.
  • Cash & Equivalents for Q4 2025 was $15.9 million at Lyra Therapeutics, down from $22.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for LYRA hit a ceiling of $122.1 million in Q2 2022 and a floor of $15.9 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $32.8 million (2024), compared with a mean of $42.4 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 76.35% in 2023 and later skyrocketed 78.38% in 2025.
  • Lyra Therapeutics' Cash & Equivalents stood at $46.1 million in 2021, then dropped by 26.33% to $33.9 million in 2022, then tumbled by 30.04% to $23.7 million in 2023, then skyrocketed by 70.89% to $40.6 million in 2024, then crashed by 60.83% to $15.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $15.9 million (Q4 2025), $22.1 million (Q3 2025), and $29.8 million (Q2 2025) per Business Quant data.